Therapix Biosciences (TRPXY) Stock Price, News & Analysis

Company Overview

Therapix Biosciences Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110, which has completed Phase II a clinical trial for the treatment of Tourette syndrome and Obstructive Sleep Apnea; THX-160, which has completed two preliminary preclinical studies for the treatment of acute and chronic pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy. Therapix Biosciences Ltd. has a collaboration with The University of Calgary to evaluate the analgesic effect of Therapix's CB2R agonist proprietary drug candidate, THX-160. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel.

Key Stats

• Today's Range: $6.00 to $6.15
• 50-Day Range: $6.03 to $6.03
• 52-Week Range: $2.75 to $22.40
• Volume: 53,500 shs
• Average Volume: 12,316 shs
• Market Capitalization: $6.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TRPXY Stock Analysis - Frequently Asked Questions

How have TRPXY shares performed this year?

Therapix Biosciences' stock was trading at $6.03 at the beginning of the year. Since then, TRPXY stock has increased by 0.0% and is now trading at $6.03.
View the best growth stocks for 2025 here.

How do I buy shares of Therapix Biosciences?

Shares of TRPXY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:TRPXY
• CUSIP: N/A
• CIK: N/A
• Web: therapixbio.com
• Phone: 972 3 616 7055
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,037,000
• Free Float: N/A
• Market Cap: $6.25 million
• Optionable: Not Optionable
• Beta: N/A